Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Valeant Finalizing Contract with Perrigo’s CEO

By AP | April 22, 2016

NEW YORK (AP) — The over-the-counter drugmaker Perrigo says it’s aware of media reports that its CEO will take the top job at troubled Valeant Pharmaceuticals, but it won’t confirm those reports.

The Wall Street Journal reported Thursday that Valeant is finalizing a contract with Perrigo Chairman and CEO Joseph C. Papa and could announced the hire as early as next week.

In this March 15, 2016 file photo, a trading post on the floor of the New York Stock Exchange displays the Valeant Pharmaceuticals logo. The Wall Street Journal reported Thursday, April 21, 2016, that Valeant is finalizing a contract with Perrigo Chairman and CEO Joseph C. Papa and could announced the hire as early as next week. Perrigo said Friday that it would not comment on “speculation or market rumor.” (AP Photo/Richard Drew)

Perrigo said Friday that it would not comment on “speculation or market rumor.”

Valeant is under heavy scrutiny in the U.S. for its strategy of buying small drugmakers, then raising prices sharply on older, off-patent drugs.

In March, Valeant said it would replace CEO Michael Pearson after billions evaporated from the company’s worth.

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news! 


Filed Under: Drug Discovery

 

Related Articles Read More >

Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority
Portrait photo of Pfizer EVP and Medtronic board member Lidia Fonseca
Medtronic appoints Pfizer EVP as independent board director

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50